Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Caribou Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
University of Oklahoma
Baylor College of Medicine
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Miami
Dartmouth-Hitchcock Medical Center
Essen Biotech
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
GeoVax, Inc.
University of Utah
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Colorado State University
University Hospital, Montpellier
Adela, Inc
Brown University
Washington University School of Medicine
VA Office of Research and Development
Zhongnan Hospital
Associazione Qol-one
AC Camargo Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Nebraska
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center